Please login to the form below

Not currently logged in
Email:
Password:

Chris Bowden joins Agios

He is former VP, product development oncology at Genentech
Agios Chris Bowden

Agios Pharma has named former Genentech VP Chris Bowden as chief medical officer.

Bowden spent eight years at Genentech as VP, product development for its oncology unit. During this time he worked on major cancer medicines, such as melanoma drug Zelboraf (vemurafenib) and Erivedge (vismodegib) for patients with unresectable, locally advanced or metastatic basal cell carcinoma.

Both drugs are now marketed by Roche since its takeover of Genentech in 2009.

Bowden's knowledge of oncology will benefit Agios as it prepares to advance the development of three candidates focused on cancer and inborn errors of metabolism.

“Agios is leading the investigation of precision medicine in the field of cellular metabolism, and has rapidly advanced several promising oral medicines to treat a range of serious diseases,” said Bowden.

Prior to working for Genentech Bowden spent three years as executive director for EMEA for Bristol-Myers Squibb. His earlier industry career includes spells as Janssen and Pharmacia.

15th May 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dovetail

We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...